Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From University of Cologne

Exelixis Fishes Artemis Out of the Ice of Germany's Biotech Winter

Exelixis Pharmaceuticals Inc.'s acquisition of its Artemis Pharmaceuticals GMBH affiliate makes strategic sense. But the bargain price paid sends a clear and frightening signal to investors in German start-ups: the real values of some of these companies--even some of those with the highest profiles--may be approaching fire-sale levels.

BioPharmaceutical Europe

US Biotech Subsidiaries in Germany

It is tempting during these dark days of the US biotech industry to contemplate establishing a presence in Europe, particularly Germany. The principal lure is funding. A typical German funding package for a US biotech could include a matching grant of $3 million by a German federal agency, alongside a $3 million investment by a German VC fund, as well as another $3 million in state and regional money.

BioPharmaceutical Europe

Germany's Biotech Boomlet

A teutonic wave of biotech start-ups is gathering, fed by government money, new venture funds and a handful of academics. But given the cultural and managerial obstacles, it's not certain that this wave will have the energy to reach the shore.

BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Academic and Research Institutions